Autopsy report · NCT03139032

Efficacy and Safety of Etrasimod (APD334) in Inflammatory Bowel Disease Patients With Active Skin Extra-intestinal Manifestations

“Sponsor decision to terminate the study”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 months before it started.
• Ran for about 5 months before it stopped.
• 1 participant enrolled.
• Results were posted on the registry 3 years 1 month after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Arena Pharmaceuticals

Sponsor type

Industry

Conditions

Inflammatory Bowel Diseases; Skin Extra-intestinal Manifestations

Interventions

APD334

Participants

1

Sites

3

Countries

Belgium, Germany, Serbia

Trials that died the same way

• Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated
  “Sponsor decision to terminate study.” (97% match in meaning)
• Study of RP-6306 With FOLFIRI in Advanced Solid Tumors
  “Sponsor decided to terminate the study” (97% match in meaning)
• A Study of ABP 215 Versus Bevacizumab in Chinese Subjects With Advanced Non-Squamous Non-Small Cell Lung Cancer
  “Sponsor decision to early terminate the study” (96% match in meaning)
• The REBALANCE Study - a Prospective, Multicenter, Randomized, Pivotal Study of the May Health System
  “Business decision by sponsor to terminate the study” (95% match in meaning)
• Safety and Efficacy of Medical Cannabis Oil in the Treatment of Patients with Chronic Pain
  “Sponsor decision to stop the study” (92% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.